(Circulation. 1996;93:2205-2211.)
© 1996 American Heart Association, Inc.
Risk-Reduction Therapy: The Challenge to Change
Presented at the 68th Scientific Sessions of the American Heart Association November 13, 1995 Anaheim, California
 |
Introduction |
|---|
One of my great pleasures as President of the American Heart Association is addressing this distinguished group as we begin our 68th Scientific Sessions.
This year we return to Anaheim. For decades our children have come here to marvel at the wonders of Disneyland. From Frontierland to Tomorrowland, they have been inspired to understand the past and think about the future, and with that, to ponder the changes that challenge their lives.
Today, we in medicine certainly face great challenge and change. Molecular biology has expanded our knowledge and the frontiers of cardiovascular science. At the same time, our healthcare system faces revolutionary change. Clinicians worry about providing optimal care for their patients, and researchers wonder about continued funding for their projects. During the next 4 days, as we share our scientific discoveries and renew friendships, many conversations will turn to these changes and challenges occurring in medicine.
This morning I want to talk about challenge and change: the challenge to bring results of research to the bedside, and the need to change our treatment strategies to emphasize risk-reduction therapy for patients with cardiovascular disease. I'd like to begin by reviewing the American Heart Association and the strategies that have made it successful.
The American Heart Association has a history of translating research
findings into effective clinical therapies and public education
programs. Founded in 1924, the American Heart Association sprang from
recommendations of five clinical cardiologists: Drs Lewis Conner, James
B. Herrick, Joseph Sailer, Paul Dudley White, and Hugh
McCullough.1
This article has been cited by other articles:
 |
|
 |
|
  J. H. Revkin, C. L. Shear, H. G. Pouleur, S. W. Ryder, and D. G. Orloff Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future Pharmacol. Rev., March 1, 2007; 59(1): 40 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K M J Douglas, A V Pace, G J Treharne, A Saratzis, P Nightingale, N Erb, M J Banks, and G D Kitas Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome Ann Rheum Dis, March 1, 2006; 65(3): 348 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Smith Jr Evidence-Based Medicine: Making the Grade: Miles to Go Before We Sleep Circulation, January 17, 2006; 113(2): 178 - 179. [Full Text] [PDF]
|
|
|
|
 |
|
 H. W. Strauss, M. Dunphy, and N. Tokita Imaging the Vulnerable Plaque: A Scintillating Light at the End of the Tunnel? J. Nucl. Med., July 1, 2004; 45(7): 1106 - 1107. [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Kensey Rheology: An Overlooked Component of Vascular Disease Clinical and Applied Thrombosis/Hemostasis, April 1, 2003; 9(2): 93 - 99. [PDF]
|
|
|
|
 |
|
 E. J. Benjamin, S. C. Smith Jr, R. S. Cooper, M. N. Hill, and R. V. Luepker Task Force #1--magnitude of the prevention problem: opportunities and challenges J. Am. Coll. Cardiol., August 21, 2002; 40(4): 588 - 603. [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Lacy, D.-C. Suh, J. A. Barone, M. Bueno, D. Moylan, C. Swartz, R. V. Kudipudi, and J. B. Kostis Impact of a Targeted Intervention on Lipid-Lowering Therapy in Patients With Coronary Artery Disease in the Hospital Setting Arch Intern Med, February 25, 2002; 162(4): 468 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. O. Akosah, R. M. Cerniglia, P. Havlik, and A. Schaper Myocardial Infarction in Young Adults With Low-Density Lipoprotein Cholesterol Levels <= 100 mg/dL : Clinical Profile and 1-Year Outcomes Chest, December 1, 2001; 120(6): 1953 - 1958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Corsini Reviews: Fluvastatin: Effects Beyond Cholesterol Lowering Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(3): 161 - 175. [Abstract] [PDF]
|
|